

1 **Supplemental Material:**

2 Blocking RpoN reduces virulence of *Pseudomonas aeruginosa* isolated from cystic fibrosis
3 patients and increases antibiotic sensitivity in a laboratory strain

4

5

6 Lloyd MG¹, Vossler JL², Nomura CT^{3,4}, Moffat JF^{1*}

7

8

9 ¹Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse,
10 NY, USA

11

12 ²Department of Clinical Laboratory Science, SUNY Upstate Medical University, Syracuse, NY,
13 USA

14

15 ³Department of Chemistry, SUNY College of Environmental Science and Forestry, Syracuse,
16 NY, USA

17


18 ⁴Center for Applied Microbiology, SUNY College of Environmental Science and Forestry,
19 Syracuse, NY, USA

20

21 *Corresponding author

22 E-mail: moffatj@upstate.edu


23



24

25 **Supplemental Figure S1. The motility phenotypes of *P. aeruginosa* CF patient isolates are**
 26 **variable.** Photograph of motility phenotypes for *P. aeruginosa* CF patient isolates. Strains
 27 include (clockwise from top left): (A and A'): UUH-0101, UUH-0201, UUH-0202, and SCH 0057-
 28 7; (B and B') SCH 0254-23, SCH 0254-116, SCH 0254-118, and SCH 0256-1; (C and C') SCH
 29 03269, SCH 0338-58, SCH 0354-1, and SCH 0397-3. All assays were performed at 37°C for 24
 30 h. (A-C) Colony diameter of swimming, or flagellar, motility assay conducted on soft (0.3%)
 31 agar. (A'-C') Colony diameter of twitching, or pili, motility assay conducted on semi-hard (1.3%)
 32 agar. White dotted circles indicate the location and size of each bacterial colony.

33



34

35 **Supplemental Figure S2. Full Immunoblots of RpoN protein in *P. aeruginosa* isolates.**

36 Immunoblots of RpoN expression in *P. aeruginosa* CF patient isolates and laboratory strains


37 PAO1-S and $\Delta rpoN$. Immunoblots performed on 10% Mini-PROTEAN TGX Stain-Free gels

38 (BioRad). Immunoblots were imaged in the same frame and under the same conditions.

39 Immunoblots were imaged for 48.372 s (optimal auto-exposure).

40

41



42

43 **Supplemental Figure S3. RpoN* expression reduced motility in *P. aeruginosa* CF patient**

44 **isolates.** Photograph of motility phenotypes for transformable *P. aeruginosa* CF patient isolates

45 including SCH 0057-7, SCH 0256-1, SCH 0338-58, and SCH 0354-1. Bacteria were

46 transformed with empty vector (W.T., pBRL344), or with RpoN*-expression vector (pBRL348).

47 The culture medium was supplemented with gentamicin (30 mg/L) and IPTG (1 mM), and

48 assays were conducted at 37°C for 24 h. (First and Second Row) Colony diameter of swimming,


49 or flagellar, motility assay conducted on soft (0.3%) agar in the absence (first row) or presence

50 (second row) of RpoN*. (Third and Fourth Row) Colony diameter of twitching, or pili, motility

51 assay conducted on semi-hard (1.3%) agar in the absence (third row) or presence (fourth row)

52 of RpoN*. White dotted circles indicate the location and size of each bacterial colony.

53



54

55 **Supplemental Figure S4. Correlation analysis of *in vitro* and *in vivo* phenotypes for *P.***

56 ***aeruginosa* CF patient isolates.** The results of the phenotyping assays presented in Figs. 1-3

57 were analyzed to determine the correlation between paired phenotypes. Correlation analyses

58 were performed using GraphPad Prism, and only twitching motility and biofilm formation were
59 significantly correlated (panel F, $p = 0.0357$). (A) Swimming or flagella-associated motility and
60 twitching or pili-associated motility. (B) Swimming motility and biofilm formation. (C) Swimming
61 motility and RpoN protein levels. (D) Swimming motility and the paralytic killing infection model.
62 (E) Swimming motility and the slow killing infection assay. (F) Twitching motility and biofilm
63 formation. (G) Twitching motility and RpoN protein levels. (H) Twitching motility and the paralytic
64 killing infection assay. (I) Twitching motility and the slow killing infection assay. (J) Biofilm
65 formation and RpoN protein levels. (K) Biofilm formation and the paralytic killing infection assay.
66 (L) Biofilm formation and the slow killing infection assay. (M) RpoN protein levels and the
67 paralytic killing infection assay. (N) RpoN protein levels and the slow killing infection assay. (O)
68 Paralytic killing and slow killing infection assays.